FDA approves first drug for acute attacks in HAE patients
This article was originally published in Scrip
Executive Summary
The US FDA has approved CSL Behring's Berinert (C1 inhibitor; C1-INH), making it the first treatment approved in the US for acute abdominal attacks and facial swelling associated with hereditary angioedema (HAE). The company plans to launch the drug in December.